Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Publication

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Journal Paper/Review - Dec 18, 2017

Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N W C J, Waage A, Beksac M, Mellqvist U H, Engelhardt M, Caers J, Driessen Christoph, Mateos M-V, Garderet L, Zweegman S, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos M A, San-Miguel J F, Terpos E, Sonneveld P

Citation

Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Mateos M, Garderet L, Zweegman S, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Sonneveld P. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. Leukemia 2017

Type

Journal Paper/Review (English)

Journal

Leukemia 2017

Publication Date

Dec 18, 2017

Issn Electronic

1476-5551

Brief description/objective

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drugs classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.Leukemia accepted article preview online, 18 December 2017. doi:10.1038/leu.2017.353.